OMO-103 + SOC
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1bActive
Key Facts
Indication
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Phase
Phase 1b
Status
Active
Company
About Peptomyc
Peptomyc is a clinical-stage biotech developing a novel class of MYC inhibitors based on its proprietary Omomyc-derived mini-protein platform. Its lead asset, OMO-103, has demonstrated safety and early clinical activity in a Phase I trial, leading to the initiation of a Phase Ib trial in pancreatic cancer and a Phase II trial in osteosarcoma. The company is positioned as a trailblazer in targeting the historically 'undruggable' MYC transcription factor, with the potential to address a high unmet need across many cancer types.
View full company profileTherapeutic Areas
Other Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Avutometinib + Defactinib | Verastem Oncology | Phase 1/2 |
| VCN-01 (zabilugene almadenorepvec) | Theriva Biologics | Phase 3 |